Injectable migraine treatment, ZEMBRACESymTouch (sumatriptan succinate) by Dr Reddy’s Laboratories, has received US Food and Drug Administration (FDA) approval
ZEMBRACESymTouch is an injectable, a drug-device combination product intended for the treatment of acute migraine episodes, with or without aura, in adults who are inadequately managed with existing treatment regimens.
The ZEMBRACESymTouch injection is intended to be given subcutaneously and is available as a prefilled, ready-to-use, single-dose disposable autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist.
Raghav Chari, executive vice president, proprietary products group at Dr Reddy's Laboratories, said: "We are pleased to have received FDA approval for ZEMBRACESymTouch, which is the first branded product in our Neurology portfolio.
“In many cases, migraine episodes are accompanied by severe nausea, making it difficult to swallow and retain pills. ZEMBRACESymTouch is specifically designed for patients who may experience certain migraine episodes and for whom a pill may not be the right option."